Hairy cell leukemia (HCL) is a rare form of chronic leukemia characterized by the proliferation of hairy cells, specialized lymphocytes that have hair-like processes. The disease is usually accompanied by hypersplenism, anemia, and lymphadenopathy. Hairy cell leukemia most often occurs in men over 50 years of age and tends to have a favorable prognosis with timely diagnosis and adequate treatment. The main characteristics of HCL include an enlarged spleen, abnormal blood counts, and other clinical symptoms that distinguish it from other forms of leukemia.
History of the disease and interesting historical facts
Hairy cell leukemia was first described in the 1970s, and its discovery was associated with the work of scientists studying tumors of the lymphatic system. One of the first steps in this research was the identification of characteristic hairy cells in bone marrow samples under a microscope. Interestingly, it was due to advances in hematology and cytology that it became possible to distinguish HCL from other forms of leukemia, such as chronic lymphocytic leukemia. The discovery of the use of interferon in the treatment of HCL in the late 20th century was a breakthrough that significantly improved the prognosis for patients.
Epidemiology
Hairy cell leukemia is a rare disease with an incidence of approximately 2–3 cases per 100,000 people per year. The disease is most commonly diagnosed in men, with an incidence of one case per 4–5 women. The peak incidence is between 50 and 60 years of age. Ethnicity data indicate a predominance in people of European descent and a low incidence in African Americans and Asians. This highlights the need for further research to elucidate possible genetic and environmental factors that contribute to the development of HCL.
Genetic predisposition to this disease
No specific genetic mutations have been identified for hairy cell leukemia to date, but it is often associated with chromosomal abnormalities such as deletion of the long arm of chromosome 5 (5q-). In some cases, mutations in the TRP53 and CDKN2A genes have been described, while other studies have implicated the BRAF gene, indicating a potential target for molecular therapy. Thus, the importance of genetic testing for individualization of therapy and assessment of the risk of disease relapse is increasing.
Risk factors for the development of this disease
There are several factors that increase the risk of developing hairy cell leukemia, including the following:
- Age: More likely in people over 50 years of age.
- Gender: Men are affected 4-5 times more often than women.
- Ethnic background: High incidence among people of European descent.
- Environmental factors: exposure to radiation and some chemicals.
- Other blood disorders: pre-existing myelodysplastic syndromes and other types of leukemia.
Diagnosis of this disease
Diagnosis of hairy cell leukemia involves a comprehensive approach based on clinical and laboratory studies. The main symptoms of the disease may include:
- Enlargement of the spleen and liver.
- Lymphadenopathy.
- Symptoms of anemia: fatigue, paleness, shortness of breath.
- Infectious complications secondary to immunodeficiency.
Laboratory tests include a complete blood count to evaluate hairy cell levels, as well as a bone marrow sample where hairy cells are visualized under a microscope. Radiologic tests such as ultrasound and CT scan of the abdomen can help determine the size of the spleen and liver. Immunophenotyping and molecular testing may be performed to aid in differential diagnosis.
Treatment
Treatment for hairy cell leukemia may vary depending on the clinical presentation and stage of the disease. Common treatment approaches include:
- Observation: in asymptomatic forms of the disease.
- Pharmacological treatment: based on the use of purine analogues such as cytosine arabioside and cladaribine.
- Immunotherapy: the use of interferons to improve the general condition.
- Surgical intervention: in some cases, surgical removal of the spleen is necessary in cases of severe hypersplenism.
There are also cases where chemotherapy may be needed, especially in combination with other forms of treatment, to achieve better results.
List of medications used to treat this disease
Treatment for hairy cell leukemia includes the following medications:
- Cytosine arabioside (Cytarabine).
- Cladribine.
- Interferon alpha.
- Fludarabine.
- Designated molecules for molecular therapy.
Disease monitoring
Monitoring of patients with hairy cell leukemia involves clinical observation and regular laboratory tests to evaluate blood proteins and cell counts. Follow-up visits should be performed every 3 to 6 months in the first years after treatment, with intervals increasing thereafter. The prognosis for most patients is favorable, especially with early diagnosis, with a 5-year survival rate of about 90%. However, patients should be alert for complications such as infections and relapses.
Age-related features of the disease
Hairy cell leukemia is most common in older patients, but it can be diagnosed in younger people. In older patients, the disease may manifest itself more aggressively, with pronounced symptoms of hypersplenism and malaise. At the same time, in younger people, the course of the disease is often milder, which allows for faster diagnosis and treatment.
Questions and Answers
- What are the main symptoms of hairy cell leukemia? The main symptoms are enlargement of the spleen and lymph nodes, fatigue, anemia and a predisposition to infections.
- Is it possible to cure VKL? With timely diagnosis and adequate treatment, most patients achieve long-term remission. Rare relapses may require repeated treatment.
- Which diagnostic method is the most effective? The most effective is a bone marrow puncture followed by microscopy for the presence of hairy cells.
- What is the relationship between VKL and genetic predisposition? Some genetic mutations, such as in the BRAF genes, may indicate a predisposition to developing HCL, but further study is needed to confirm the link.
- Is there a prevention for hairy cell leukemia? There is no specific prevention, but maintaining a healthy lifestyle and avoiding chemical carcinogens can reduce the risk of a number of blood diseases.
Advice from Dr. Oleg Korzhikov
According to Dr. Oleg Korzhikov, patients with hairy cell leukemia should pay attention to regular medical examinations to detect any changes in their health early. “The most important aspect of treatment is maintaining psychological comfort and creating a support network for patients and their families,” he noted. The use of new molecular diagnostics and therapy methods opens up new horizons in the treatment of HCL, so it is important to be aware of the latest advances in medicine and take an active part in your own treatment.
